Royce & Associates LP grew its stake in Azenta, Inc. (NASDAQ:AZTA - Free Report) by 7.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 739,977 shares of the company's stock after purchasing an additional 53,584 shares during the period. Royce & Associates LP owned approximately 1.51% of Azenta worth $35,844,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently bought and sold shares of AZTA. BNP Paribas Financial Markets lifted its position in shares of Azenta by 43.5% during the first quarter. BNP Paribas Financial Markets now owns 13,672 shares of the company's stock worth $824,000 after purchasing an additional 4,144 shares during the last quarter. Janney Montgomery Scott LLC grew its stake in Azenta by 9.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 5,167 shares of the company's stock worth $311,000 after acquiring an additional 438 shares in the last quarter. Envestnet Portfolio Solutions Inc. increased its position in shares of Azenta by 1.7% during the first quarter. Envestnet Portfolio Solutions Inc. now owns 13,488 shares of the company's stock worth $813,000 after acquiring an additional 229 shares during the period. Russell Investments Group Ltd. increased its position in shares of Azenta by 9.5% during the first quarter. Russell Investments Group Ltd. now owns 4,698 shares of the company's stock worth $283,000 after acquiring an additional 409 shares during the period. Finally, State Board of Administration of Florida Retirement System raised its stake in shares of Azenta by 6.8% during the first quarter. State Board of Administration of Florida Retirement System now owns 74,608 shares of the company's stock valued at $4,497,000 after acquiring an additional 4,739 shares in the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research firms have commented on AZTA. Evercore ISI reduced their price objective on Azenta from $53.00 to $50.00 and set an "in-line" rating on the stock in a report on Tuesday, October 1st. Needham & Company LLC cut their price target on Azenta from $69.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Azenta currently has an average rating of "Hold" and a consensus price target of $63.60.
Read Our Latest Stock Report on AZTA
Insider Buying and Selling
In other Azenta news, CFO Herman Cueto sold 1,595 shares of the stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $43.68, for a total transaction of $69,669.60. Following the sale, the chief financial officer now directly owns 24,604 shares of the company's stock, valued at approximately $1,074,702.72. This trade represents a 6.09 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.77% of the stock is currently owned by company insiders.
Azenta Stock Down 2.6 %
Shares of Azenta stock traded down $1.12 during trading on Friday, reaching $41.51. The company's stock had a trading volume of 525,163 shares, compared to its average volume of 500,342. Azenta, Inc. has a 1-year low of $40.24 and a 1-year high of $69.16. The company has a 50-day simple moving average of $45.68 and a two-hundred day simple moving average of $50.54.
Azenta (NASDAQ:AZTA - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.10 by $0.08. The firm had revenue of $170.00 million during the quarter, compared to analyst estimates of $169.66 million. Azenta had a negative net margin of 25.01% and a positive return on equity of 1.03%. Azenta's revenue was down 1.2% on a year-over-year basis. During the same period last year, the firm posted $0.13 EPS. Equities research analysts forecast that Azenta, Inc. will post 0.42 EPS for the current fiscal year.
About Azenta
(
Free Report)
Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.
Further Reading
Before you consider Azenta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Azenta wasn't on the list.
While Azenta currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
